BIOMAT Database Logo BIOMAT Database Logo

In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta-lactams, erythromycin, and tetracycline. 1996

R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
Pasteurinstituut, Eenheid Antibiotica-onderzoek, Brussel.

One hundred seventy six consecutive, non-duplicate pneumococcal isolates from clinical specimens collected from November 1994 through February 1995 in nine general hospitals throughout Belgium were tested for their in vitro susceptibilities to penicillin, ampicillin, amoxycillin with and without clavulanate, cefaclor, cefuroxime, cefonicid, cefprozil, cefpodoxime, cefotaxime, imipenem, tetracycline, and erythromycin by means of the NCCLS microdilution test. The overall rate of decreased susceptibility to penicillin was 12.5%, including 6.3% of intermediately and 6.3% of fully resistant isolates. Penicillin, ampicillin amoxycillin, amoxycillin/clavulanate, cefuroxime, cefotaxime and imipenem had the highest activity on a weight basis (MIC50 < or = 0.008 microgram/ml), followed by cefpodoxime and erythromycin (MIC50 of 0.015 microgram/ml), cefprozil and tetracycline (MIC50 of 0.12 microgram/ml), and eventually, cefaclor and cefonicid (MIC50 of 0.5 microgram/ml). Aggregate rates of susceptible plus intermediately resistant isolates at NCCLS-recommended breakpoints, i.e. overall percentages of isolates likely to respond to increased antibiotic doses in vivo (except for meningitis), were 100.0% for imipenem and cefotaxime, 98.9% for amoxycillin with and without clavulanate, 93.8% for penicillin, and 90.9% for cefuroxime. Overall rates of susceptibility to erythromycin and tetracycline amounted to 78.4% and 72.7%, respectively. MIC values of all beta-lactams increased with those of penicillin. Ampicillin was equally active as penicillin against isolates with reduced susceptibility to the latter (MIC90 of 2 micrograms/ml); imipenem, cefotaxime, and amoxycillin with and without clavulanate however, were more active (MIC90 3, 1, and 1 doubling dilution, respectively, below that of penicillin), while cefpodoxime, cefuroxime, cefprozil, cefonicid, and cefaclor on the other hand, were less active (MIC90, 1, 1, 2, 5, and 5 doubling dilutions, respectively, above that of penicillin). In conclusion, the present data confirm that pneumococcal resistance to penicillin has increased in Belgium, suggest that resistance to erythromycin may have stabilised, and reveal an unexpectedly high rate of resistance to tetracycline. Imipenem was the most active antibiotic tested overall, and amoxycillin with or without clavulanate the most active oral antibiotic, with activity almost similar to that of cefotaxime.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011008 Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus
D013752 Tetracycline A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis. 4-Epitetracycline,Achromycin,Achromycin V,Hostacyclin,Sustamycin,Tetrabid,Tetracycline Hydrochloride,Tetracycline Monohydrochloride,Topicycline,4 Epitetracycline
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams

Related Publications

R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
August 2006, Pathology,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In-vitro activity of a combination of two oral beta-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.
October 1998, The Journal of antimicrobial chemotherapy,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.
September 2004, Antimicrobial agents and chemotherapy,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime.
October 2003, Antimicrobial agents and chemotherapy,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.
November 1998, Antimicrobial agents and chemotherapy,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
Molecular epidemiology, antimicrobial susceptibilities and resistance mechanisms of Streptococcus pyogenes isolates resistant to erythromycin and tetracycline in Spain (1994-2006).
September 2012, BMC microbiology,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities.
July 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.
July 2003, Antimicrobial agents and chemotherapy,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
[Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin].
March 2006, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
R Vanhoof, and M Carpentier, and Y Glupczynski, and B Gordts, and K Magerman, and H J Nyssen, and A Simon, and I Surmont, and M Van de Vyvere, and H Van Landuyt, and L Van Nimmen, and R Van Noyen
In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.
October 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Copied contents to your clipboard!